BFM
MRNS

Boothbay Fund Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Boothbay Fund Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-56,300
Closed -$509K – 1952
2024
Q1 		$509K Buy
+56,300
New +$547K 0.01% 994
2022
Q2 		– Sell
-33,300
Closed -$311K – 2774
2022
Q1 		$311K Buy
+33,300
New +$331K 0.01% 1591
2018
Q4 		– Sell
-330
Closed -$1.32M – 948
2018
Q3 		$1.32M Buy
+330
New +$9.39K 0.13% 152

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boothbay Fund Management's MRNS Position: Q4 2024 in Review

Boothbay Fund Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 185,996 shares — an estimated $327K sold.

Boothbay Fund Management first reported a position in MRNS in Q4 2015 and held it in 14 quarters. The position peaked at $4.49M in Q2 2023. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Boothbay Fund Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 185,996 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $327K.
  • Boothbay Fund Management first reported a position in Marinus Pharmaceuticals, Inc in Q4 2015 and held it in 14 quarters.
  • Boothbay Fund Management's Marinus Pharmaceuticals, Inc position peaked at $4.49M in Q2 2023.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Boothbay Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.